# A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)

> **NCT06615206** · NA · RECRUITING · sponsor: **HuidaGene Therapeutics Co., Ltd.** · enrollment: 6 (estimated)

## Conditions studied

- MECP2 Duplication Syndrome

## Interventions

- **GENETIC:** HG204

## Key facts

- **NCT ID:** NCT06615206
- **Lead sponsor:** HuidaGene Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2024-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06615206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06615206, "A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06615206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*